Clear Street Reaffirms Their Buy Rating on Y-Mabs Therapeutics (YMAB)
Clear Street analyst William Maughan reiterated a Buy rating on Y-Mabs Therapeutics (YMAB – Research Report) today and set a price target of $17.00. The company's shares closed today at $4.62.
Confident Investing Starts Here:
Maughan covers the Healthcare sector, focusing on stocks such as Y-Mabs Therapeutics, Delcath Systems, and Summit Therapeutics. According to TipRanks, Maughan has an average return of 18.5% and a 49.37% success rate on recommended stocks.
In addition to Clear Street, Y-Mabs Therapeutics also received a Buy from H.C. Wainwright's Robert Burns in a report issued on May 19. However, on May 13, Morgan Stanley maintained a Sell rating on Y-Mabs Therapeutics (NASDAQ: YMAB).
Based on Y-Mabs Therapeutics' latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $20.9 million and a GAAP net loss of $5.2 million. In comparison, last year the company earned a revenue of $19.93 million and had a GAAP net loss of $6.63 million
Based on the recent corporate insider activity of 23 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of YMAB in relation to earlier this year. Most recently, in March 2025, Thomas Gad, the CBO of YMAB sold 10,810.00 shares for a total of $56,536.30.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
33 minutes ago
- Yahoo
Fortrea Names Anshul Thakral Chief Executive Officer
Thakral succeeds Interim CEO, Peter M. Neupert, who will remain chairman of the board DURHAM, N.C., June 11, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the 'Company'), a leading global contract research organization (CRO), today announced that Fortrea's Board of Directors (the 'Board') named Anshul Thakral as Fortrea's CEO, effective August 4, 2025. He was also appointed to serve as a director on the Company's Board, effective as of that date. Thakral succeeds Interim CEO, Peter M. Neupert, who will remain as chairman of the board. Thakral brings more than 20 years of experience in life sciences as an executive and commercial leader, advisor and entrepreneur. He will focus on executing the Company's transformation plan and sharpening Fortrea's focus on profitable growth. Further, he will oversee additional value creation efforts for customers, employees and shareholders. 'Anshul is an exceptional leader with extensive life sciences experience, deep familiarity with the CRO industry, a commitment to innovation and a proven record of building companies and growing revenue,' said Neupert. 'His strong business development capabilities, commercial insights and relentless focus on customer engagement make him ideally suited to lead Fortrea. Further, he also shares the Company's commitment to modernizing the clinical trials process and combining the best talent, science and technology to effectively and efficiently respond to changing customer and patient needs. We are delighted to welcome Anshul to Fortrea as we seek to capitalize on the significant growth opportunities we see ahead and meet our customers' needs.' 'Since its founding, the Fortrea team has earned a strong reputation for leading with science and creating a differentiated customer experience,' said Thakral. 'I share the team's passion for customers and the patients they serve, and I'm honored to take the reins at this pivotal moment. It is an exciting opportunity to lead the organization as it continues to deliver flexible and agile drug development solutions that accelerate the delivery of life-changing treatments to patients. I'm confident this company can execute on its patient and customer-focused mission while delivering profitable growth, which ultimately delivers value for shareholders.' About Anshul Thakral Thakral joins Fortrea from Launch Therapeutics, a company he co-founded at which he served as CEO. Previously, he held several executive leadership roles at PPD, a leading CRO, including chief commercial officer and executive vice president of Peri- and Post-Approval Services. He led PPD Biotech, which contributed to PPD's growth. Prior to PPD, Thakral ran the global life sciences business unit at Gerson Lehrman Group and served as an Associate Principal at McKinsey & Company in the healthcare practice. He currently serves on the board of directors of TriNetX, Saama Technologies and Orsini Specialty Pharmacy. He earned his B.S. and M.S.E. in Biomedical Engineering from Johns Hopkins University and his MBA from the Wharton School at the University of Pennsylvania. About Fortrea Fortrea (Nasdaq: FTRE) is a leading global provider of clinical development solutions to the life sciences industry. We partner with emerging and large biopharmaceutical, biotechnology, medical device and diagnostic companies to drive healthcare innovation that accelerates life changing therapies to patients. Fortrea provides phase I-IV clinical trial management, clinical pharmacology and consulting services. Fortrea's solutions leverage three decades of experience spanning more than 20 therapeutic areas, a passion for scientific rigor, exceptional insights and a strong investigator site network. Our talented and diverse team working in about 100 countries is scaled to deliver focused and agile solutions to customers globally. Learn more about how Fortrea is becoming a transformative force from pipeline to patient at and follow us on LinkedIn and X (formerly Twitter). Cautionary Statement Regarding Forward-Looking Statements This press release contains 'forward-looking statements' within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, without limitation, the Company's growth opportunities. In this context, forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as 'guidance,' 'expect,' 'assume,' 'anticipate,' 'intend,' 'plan,' 'forecast,' 'believe,' 'seek,' 'see,' 'will,' 'would,' 'target,' similar expressions, and variations or negatives of these words that are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from the Company's expectations due to a number of factors, including, but not limited to, the following: the Company's ability to successfully implement its business strategies and execute its long-term value creation strategy; risks and expenses associated with the Company's international operations, tariff policies, trade sanctions and other trade restrictions and currency fluctuations; the Company's customer or therapeutic area concentrations; any further deterioration in the macroeconomic environment or further changes in government regulations and funding, which could lead to defaults or cancellations by the Company's customers; the risk that the Company's backlog and net new business may not be indicative of the Company's future revenues and that the Company might not realize all of the anticipated future revenue reflected in the Company's backlog; the Company's ability to generate sufficient net new business awards, or the possibility that net new business awards are delayed, terminated, reduced in scope, or fail to go to contract; if the Company underprices its contracts, overruns its cost estimates, or fails to receive approval for, or experiences delays in documentation of change orders; and other factors described from time to time in documents that the Company files with the SEC. For a further discussion of the risks relating to the Company's business, see the 'Risk Factors' Section of the Company's Annual Report on Form 10-K for the year ended December 31, 2024, as filed with the Securities and Exchange Commission (the "SEC"), as such factors may be amended or updated from time to time in the Company's subsequent periodic and other filings with the SEC, which are accessible on the SEC's website at These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in this release and in the Company's filings with the SEC. All forward-looking statements are made only as of the date of this release and the Company does not undertake any obligation, other than as may be required by law, to update or revise any forward-looking statements to reflect future events or developments. Contacts: Hima Inguva (Investors) – 877-495-0816, Sue Zaranek (Media) – 919-943-5422, media@ Kate Dillon (Media) – 646-818-9115, kdillon@ A photo accompanying this announcement is available at in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
36 minutes ago
- Yahoo
CSX Announces Ratification of Labor Deal with Locomotive Engineers
JACKSONVILLE, Fla., June 11, 2025 (GLOBE NEWSWIRE) -- CSX Corporation (NASDAQ: CSX) today announced that employees represented by the Brotherhood of Locomotive Engineers and Trainmen (BLET) have voted to ratify the five-year collective bargaining agreement covering approximately 3,400 locomotive engineers. This is the first ratification reached by a Class I freight railroad with BLET. 'The ratified agreement demonstrates the value of our partnership with BLET, our CSX General Chairmen, and our shared commitment to improving the day-to-day experience for our locomotive engineers,' said Joe Hinrichs, President and CEO of CSX. 'I want to thank our engineers for their unwavering dedication to our customers and the communities in which we live and work. This is a significant milestone for our people and the future of our railroad.' The agreement mirrors the general wage increases, and health and welfare improvements from CSX's agreements with 13 other unions. Locomotive engineers make up approximately 20 percent of CSX's frontline workforce. To date, nearly 75 percent of CSX unionized workers are now covered by new agreements reached within the last 10 months. The only remaining major workgroup at CSX not covered by new agreements or a tentative agreement are trainmen/conductors represented by SMART-TD. CSX is currently engaged in bargaining with SMART-TD to consolidate separate territories, workforces, and execute a single-system collective agreement. About CSX CSX, based in Jacksonville, Florida, is a premier transportation company. It provides rail, intermodal and rail-to-truck transload services and solutions to customers across a broad array of markets, including energy, industrial, construction, agricultural and consumer products. For nearly 200 years, CSX has played a critical role in the nation's economic expansion and industrial development. Its network connects every major metropolitan area in the eastern United States, where nearly two-thirds of the nation's population resides. It also links more than 240 short-line railroads and more than 70 ocean, river and lake ports with major population centers and farming towns alike. More information about CSX Corporation and its subsidiaries is available at Like us on Facebook ( and follow us on X, formerly known as Twitter ( Contact: Matthew Korn, CFA, Investor Relations904-366-4515 Bryan Tucker, Corporate Communications 855-955-6397Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
43 minutes ago
- Yahoo
UK Regulator Partners with Nvidia to Help Banks Test AI Tools
NVIDIA Corporation (NASDAQ:NVDA) is one of the best Dow stocks to invest in. Recently, Britain's financial regulator announced a partnership with the company to help banks safely explore artificial intelligence technologies. The Financial Conduct Authority (FCA) revealed plans to launch a new 'Supercharged Sandbox' in October, aimed at supporting financial institutions in the early stages of AI experimentation. Through this initiative, firms will gain access to NVIDIA Corporation (NASDAQ:NVDA)'s accelerated computing tools and AI Enterprise Software, along with improved data, technical expertise, and regulatory guidance to help speed up innovation. A close-up of a colorful high-end graphics card being plugged in to a gaming computer. The FCA noted that this program is intended for companies still in the early "discovery and experiment" stage of AI adoption, while a separate testing environment is already available for firms further along in development. Jessica Rusu, the FCA's chief data, intelligence and information officer, made the following comment: 'This collaboration will help those that want to test AI ideas but who lack the capabilities to do so. We'll help firms harness AI to benefit our markets and consumers, while supporting economic growth.' NVIDIA Corporation (NASDAQ:NVDA) produces the graphics processing units (GPUs) that power the training and operation of advanced AI models. The stock has surged by nearly 4% since the start of 2025. While we acknowledge the potential of NVDA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
